|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
AstraZeneca PLC (AZN) Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2
12/5/2012 10:35:59 AM
WILMINGTON, Del.--(BUSINESS WIRE)--Today, updated overall survival (OS) data for FASLODEX® (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following prior endocrine therapy was presented at the 35th CTRC-AACR San Antonio Breast Cancer Symposium by the principal investigator, Angelo Di Leo, MD, Head of the Sandro Pitigliani Medical Oncology Unit.1,2,3. The final updated CONFIRM OS, performed at 75% maturity (after a minimum follow up duration of 50 months), showed a 19% relative reduction in the risk of death (hazard ratio (HR) 0.81; 95% confidence interval [CI] 0.69-0.96). No adjustments were made for multiplicity, therefore these data cannot be considered statistically significant. The median OS for FASLODEX 500 mg and 250 mg was 26.4 months and 22.3 months, respectively.2
|
|
|
|
|
|
|
|
|
|
|